What is Peptide Manual?

Adjust common research variables — per-dose, frequency, body weight, and duration — and see how they influence modeled exposure and a projected research-response index based on standardized literature-derived ranges.

How this calculator works

Adjust common research variables — per-dose, frequency, body weight, and duration — to see how they influence modeled exposure and a projected research-response index. The model uses a saturating Emax curve anchored to each peptide's research profile and standardized literature-derived reference ranges.Reference values are approximate ranges discussed in published research, standardized for educational modeling — not dosing recommendations.

Protocol

Peptide

Early Human ResearchFamily: Body Protection Compound· Route: Subcutaneous· t½ ≈ 1h

Per-dose6 mcg/kg · 480 mcg

Typical studied: 2–10 mcg/kgWithin typical

Frequency5× / week

Body weight80 kg

Duration4 weeks

Typical studied up to 4 weeksWithin studied

Per dose

480 mcg

6 mcg/kg

Weekly total

2.40 mg

5 doses/wk

Course total

9.60 mg

4 weeks

Accumulation

1.00×

steady-state vs first dose

Dose → Response

Modeled research-response index (0–100) across a dose range. The dot marks your current per-dose.

Projected response by area

Saturating Emax projection per research area at your current settings (bar) vs the peptide's max studied score (faded).

Compare Protocols

Compare educational protocol summaries by research goal, peptides involved, evidence level, and limitations.

Attribute	Recovery Protocol Recovery	Weight Management Protocol Weight Management
Research Goal	Recovery	Weight Management
Peptides Involved	5 peptides	14 peptides
Key Peptides	BPC-157, TB-500, Thymosin Beta-4, PEG-MGF	AOD-9604, Tesamorelin, Retatrutide, Tirzepatide
Evidence Level	Moderate Confidence	Extensive Confidence
Research Status	Clinical Research	Approved Medication
Typical Study Duration	Weeks to months (varies by study)	Weeks to months (varies by study)
Mechanisms	Upregulates angiogenesis and growth factor expression; Binds actin and promotes cell migration; Actin-sequestering peptide promoting cell migration	Lipolytic fragment of growth hormone; Stabilized GHRH analog; GLP-1, GIP, and glucagon receptor agonist
Research Limitations	3 of the peptides in this protocol have human data (clinical or early human). Combination-specific human trials are limited.	11 of the peptides in this protocol have human data (clinical or early human). Combination-specific human trials are limited.

Educational information only

These protocols are educational summaries based on published literature and are not individualized medical advice. Protocols, dosing, preparation, and monitoring vary by study, product, and clinical context. Decisions about treatment should be made with a qualified healthcare professional. The content on Peptide Manual is for informational and educational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any condition. Always consult a qualified healthcare professional before making health decisions.